Ligand Pharmaceuticals Incorporated stock is up 2.21% since 30 days ago. The next earnings date is May 2, 2024. The company has had above-average volume in the last 30 days. Its seasonality going into this month shows a chance of a green month, as 68.42% of the previous 18 March’s closed higher than February. In the last 2 Unusual Options Trades, there were 1 CALL, 1 PUT. 100% of analysts rate it a buy.
Ligand Pharmaceuticals Incorporated focuses on developing or acquiring technologies that help pharmaceutical companies to discover and develop medicines worldwide. Its commercial programs include Kyprolis and Evomela, which are used to treat multiple myeloma; Veklury for the treatment of moderate or severe COVID-19; Teriparatide injection product for osteoporosis; Vaxneuvance for the prevention of invasive disease caused by Streptococcus pneumoniae. The company also offers Rylaze, a recombinant erwinia asparaginase, and Nexterone, a captisol-enabled formulation of amiod
Unlock Exclusive Market Insights! Receive timely updates on market developments. Sign up & stay informed!